Absci to Participate in the 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Absci Corporation (Nasdaq: ABSI) announced its participation in the 41^st Annual J.P. Morgan Healthcare Conference in San Francisco on January 12^th at 8:15 a.m. PT. The event can be accessed via a live and archived webcast on the company's investor relations website.

Absci is focused on generative AI drug discovery, utilizing deep learning and synthetic biology to create innovative biotherapeutics. Their Integrated Drug Creation™ platform enables the identification of new drug targets and the development of protein-based drugs.

VANCOUVER, Wash. and NEW YORK, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming 41^st Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Absci management is scheduled to present on Thursday, January 12^th at 8:15 a.m. Pacific Time (11:15 a.m. Eastern Time). Interested parties may access a live and archived webcast of the presentation on the company’s investor relations website at: investors.absci.com.

About Absci

Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic™ proteins containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com and follow us on social media: Twitter: @Abscibio, LinkedIn: @absci, and subscribe to our Absci YouTube channel.

Availability of Other Information about Absci

Investors and others should note that we routinely communicate with investors and the public using our website (www.absci.com) and our investor relations website (investors.absci.com), including without limitation, through the posting of investor presentations, SEC filings, press releases, public conference calls and webcasts on these websites, as well as on Twitter, LinkedIn and YouTube. The information that we post on these websites and social media outlets could be deemed to be material information. As a result, investors, the media, and others interested in Absci are encouraged to review this information on a regular basis. The contents of our website and social media postings, or any other website that may be accessed from our website or social media postings, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Investor Contact
investors@absci.com

Media Contact
press@absci.com

FAQ

When will Absci participate in the J.P. Morgan Healthcare Conference?

Absci will present at the 41st Annual J.P. Morgan Healthcare Conference on January 12th at 8:15 a.m. Pacific Time.

How can I access Absci's presentation at the J.P. Morgan Healthcare Conference?

The presentation can be accessed through a live and archived webcast on Absci's investor relations website.

What is Absci's focus in drug discovery?

Absci specializes in generative AI drug creation, using deep learning and synthetic biology to develop innovative biotherapeutics.

What is the mission of Absci Corporation?

Absci aims to enhance medicine development by leveraging its Integrated Drug Creation™ platform for creating novel protein-based drugs.

Where can I find more information about Absci Corporation?

For more information about Absci, visit their official website at www.absci.com.